Showing results (991-1000 of 1,192) with videos related to
Sort By:
Pageof 120
American Journal of Hematology|August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Matteo Molica, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemiaDaniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.Cancer|October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutationsMahran Shoukier, Tapan Kadia, Marina Konopleva, et al.Leukemia & Lymphoma|October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapyJorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsNaval G Daver, Paresh Vyas, Suman Kambhampati, et al.Oncotarget|March 9, 2018
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasmsGuillermo Montalban-Bravo, Koichi Takahashi, Keyur Patel, et al.Blood Advances|April 25, 2020
Clinical value of event-free survival in acute myeloid leukemiaAbhishek Maiti, Hagop M Kantarjian, Vinita Popat, et al.American Journal of Hematology|April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk diseaseAndrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.Blood|October 27, 2007
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesGuillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, et al.American Journal of Hematology|June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantationAlexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.Pageof 120